Johnson & Johnson

Equities

JNJ

US4781601046

Pharmaceuticals

Market Closed - Nyse 04:00:02 2024-05-29 pm EDT 5-day change 1st Jan Change
144.4 USD +0.04% Intraday chart for Johnson & Johnson -5.90% -7.85%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Transcript : Johnson & Johnson Presents at Bernstein?s 40th Annual Strategic Decisions Conference, May-29-2024 01:30 PM
J&J: encouraging results in the treatment of depression CF
Johnson & Johnson's Phase 3 Trial of Seltorexant to Treat Major Depressive Disorder Meets Primary, Secondary Endpoints MT
J&J's treatment for depression succeeds in late stage study RE
Sector Update: Health Care Stocks Fall Late Afternoon MT
Sector Update: Health Care Stocks Retreat Tuesday Afternoon MT
Sector Update: Health Care MT
Bio-Thera, Stada Enter Deal for Biosimilar Candidate to Johnson & Johnson's Simponi in EU, UK MT
Johnson & Johnson Agrees to Buy Numab Unit, Investigational Skin Disease Treatment For $1.25 Billion MT
Top Midday Stories: Wall Street Returns to T+1 Settlements; T-Mobile Buys US Cellular's Wireless Ops; Energy Transfer Buys WTG Midstream; GameStop Extends Rally MT
Johnson & Johnson to Acquire Experimental Eczema Drug for $1.25 Billion MT
Johnson & Johnson to Acquire Experimental Eczema Drug for $1.25 Billion MT
Johnson & Johnson Acquires Experimental Eczema Drug for $1.25 Billion MT
J&J: acquisition of Swiss eczema biotech company CF
J&J to Acquire Skin Disease Treatment Rights from Numab in $1.25 Billion Deal DJ
J&J acquires rights to skin disorder drug for $1.25 bln RE
J&J: to present advances at ASCO and EHA CF
Some of the biggest splits in Corporate America RE
Cancer victims sue Johnson & Johnson over 'fraudulent' bankruptcies RE
Johnson & Johnson Allegedly Engaged in 'Bad Faith' Bankruptcies That Harm Talc Victims, Lawsuit Says MT
Top Midday Stories: US Targets August 1 Start Date for China Tariff Hikes; CFPB Says BNPL Requires Credit Card-Level Oversight; Target Shares Fall on Earnings Miss; Third BHP Bid Rejected by Anglo American MT
Johnson & Johnson Allegedly Engaged in 'Bad Faith' Bankruptcies That Harm Talc Victims, Lawsuit Says MT
Nanobiotix to Transfer Phase 3 Head and Neck Cancer Study Sponsorship MT
J&J: positive trial for Tremfya in ulcerative colitis CF
Valneva Names New Chief Scientific Officer MT
Chart Johnson & Johnson
More charts
Johnson & Johnson is one of the world's leading producers of healthcare products. Net sales break down by family of products as follows: - pharmaceutical products (55.4%): drugs intended for the treatment of cardiovascular diseases, oncological diseases, gastro-intestinal illnesses, infectious, immunological, neurological, dermatological diseases, etc.; - medical products and equipment (28.9%): diagnostic systems, orthopedic and gynecological equipment, surgical materials, etc. for use by healthcare professionals; - consumer health products (15.7%): OTC drugs (Tylenol, Sudafed, Benadryl, Zyrtec, Motrin, Nicorette and other brands), health and beauty products (Aveeno, Clean & Clear, Dr. CI:Labo, Neutrogena and OGX), baby care products (Johnson's and Aveeno Baby), oral care products (Listerine), feminine hygiene products (Stayfree and Carefree and o.b.), wound care products (Band-Aid and Neosporin) etc. At the end of 2022, Johnson & Johnson has 89 manufacturing facilities located in the United States (28), North America (9), Europe (27), Africa and Asia/Pacific (25). Net sales are distributed geographically as follows: the United States (51.2%), Europe (24.7%), Asia/Pacific and Africa (17.7%) and other (6.4%).
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
22
Last Close Price
144.4 USD
Average target price
172.5 USD
Spread / Average Target
+19.44%
Consensus
  1. Stock Market
  2. Equities
  3. JNJ Stock
  4. News Johnson & Johnson
  5. Tanzania, Rwanda Latest to Recall Batch of Johnson & Johnson's Infant Cough Syrup